From São Paulo to Rio: what Brazil taught me about menopause care

Dr Susie Rockwell • November 19, 2026

Last month I returned from an extraordinary couple of weeks in Brazil with two impressions that, at first glance, seem to pull in opposite directions and a question that has stayed with me: how do we combine genuinely personalised menopause care with treatment that is safe, evidence-based and accessible? In São Paulo, I saw an extraordinary range of hormonal and lifestyle products. A few days later in Rio, conversations with colleagues from around the world reminded me that having more choice does not necessarily mean that everyone can access it.


Here is what the trip taught me...


São Paulo: a marketplace of hormonal choice

My first stop was São Paulo, where I had the privilege of presenting at a conference on menopause and ‘Endohacking’ – the growing field of using hormones, supplements and lifestyle tools to optimise how we feel and function through midlife and beyond.


What struck me most was the sheer range of hormonal and lifestyle products available to people there. Much of this is down to Brazil's compounding pharmacies (farmácias de manipulação), which are a familiar part of everyday healthcare. These pharmacies make up medicines to an individual prescription, so a doctor can ask for a particular hormone in a particular dose, strength and form – a cream, a gel, a capsule, a lozenge – rather than choosing from a fixed list of licensed products.


The result is that Brazilian women (and men) have far greater availability and choice than we do in the UK, where we rely almost entirely on licensed, manufactured products, and where shortages of particular patches or gels have at times left women scrambling to find an alternative.


There is a great deal to admire in that flexibility, and a real lesson for us about tailoring treatment to the individual. But I also want to be balanced. Compounded hormones don't go through the same licensing, testing and quality checks as licensed medicines, and doses can vary from batch to batch. At The Women’s Hormone Clinic, we use two compounding pharmacies when there is no suitable licensed equivalent. The British Menopause Society and NICE continue to recommend regulated, body-identical products wherever possible. Choice is wonderful – but it needs to sit alongside evidence and safety.




Rio: 4,000+ menopause experts under one roof

From São Paulo I travelled to Rio de Janeiro for the 20th World Congress on Menopause, hosted by the International Menopause Society (IMS) from 30 September to 3 October 2026. It sold out, with more than 4,000 delegates from over 80 countries. It is remarkable to think that the very first international congress on menopause, fifty years ago, was attended by just 165 people. Menopause is, at last, a mainstream conversation.


The science was fascinating, but what stayed with me most were the conversations with colleagues from other countries. Again and again it became apparent that, within the state-funded healthcare systems of several countries, women have far less access to menopausal hormone therapy (MHT, often called HRT) than we do in the UK. For those of us who spend our working lives pushing for better menopause care at home, it was a genuinely humbling perspective.


Brazil and beyond: choice for some, not for all

It would be easy to come away from São Paulo thinking that Brazilian women are spoilt for choice. But that choice largely belongs to those who can pay for it. Within Brazil's public health service, the SUS, the picture is very different. Brazilian clinicians have pointed out that the SUS offers essentially one option for hormone therapy, and that what we in the UK would consider first-line treatment – transdermal oestradiol gel or patches with micronised progesterone – has not been available through it. Meanwhile, private-sector menopause care has modernised rapidly. In other words, Brazil has both ends of the spectrum: remarkable choice in the private market, and very limited options in the state system.


Encouragingly, this is starting to change. In 2026 Brazil's Ministry of Health issued new technical guidance on care through the menopause transition, and in October 2026 the body that assesses medicines for the SUS opened a public consultation on providing oestradiol, alone or with progesterone, for women aged 40 and over with moderate to severe hot flushes.


Further afield, the gaps are often wider still. Research in low- and middle-income countries has found that many have no national menopause guidelines, and that HRT is often missing from their essential medicines lists, which makes it hard to obtain at all. Just a few weeks after the Congress, the Pan American Health Organization called on countries across Latin America and the Caribbean to strengthen menopause care within their health services.


Brazil brought a distinction into sharp focus for me: the range of treatments available in a country tells only part of the story. Just as important is who can actually access them. The flexibility I saw in São Paulo was striking, but the contrast between private choice and public provision was a reminder that personalisation and accessibility need to go hand in hand.


What I brought home from Brazil

I came home with a renewed appreciation of access to menopause treatment through the NHS, but also with a reminder that there is still work to do. Long waits for menopause clinics, patchy GP training and periodic shortages of key products remain part of the picture. Learning from colleagues overseas should encourage us to value what works at home without becoming complacent about what needs to improve.


Above all, Brazil reminded me that menopause care should never be one-size-fits-all. For me, the lesson is to combine the safety and evidence of regulated medicines with real personalisation – the right treatment, at the right dose, in the right form for you, alongside an individual discussion about diet, supplements and lifestyle support.


That is exactly what we aim to offer at the Women's Hormone Clinic.


If you would like to talk through your options, please click here to book a consultation.



Further reading

  • International Menopause Society – 20th World Congress on Menopause, Rio de Janeiro, 2026
  • NICE guideline NG23 – Menopause: identification and management
  • Ministério da Saúde (Brazil) – Nota Técnica Conjunta nº 72/2026: Transição menopausal, menopausa e pós-menopausa
  • Pan American Health Organization – PAHO calls for stronger menopause care to promote healthy aging in the Americas (November 2026)
  • Delanerolle G, et al. A perspective on economic barriers and disparities in access to hormone replacement therapy in LMICs (MARIE-WP2b). Scientific Rep
  • orts, 2026
By Dr Ayana Gibbs • November 18, 2026
Fatigue can be as debilitating as pain in endometriosis. New genetic research suggests it deserves more attention in research and clinical care.
By Dr Ginny Ponsford • November 16, 2026
After a week teaching GPs and meeting researchers in Harare, I share why menopause is a public health issue in Zimbabwe and what needs to happen next.
By Dr Louise Horrocks • November 16, 2026
Today I attended the Oliver McGowan Mandatory Training on Learning Disability and Autism. As a GP with a special interest in women's health, it has prompted me to reflect on how we can make healthcare more accessible, inclusive and responsive to the needs of every woman.
By Dr Ayana Gibbs • November 11, 2026
A personal journey to Bioko Island, exploring African ancestry, Bubi culture, menopause and the changing meaning of identity in midlife.
By Dr Kemi Adeyemi • October 12, 2026
Learn how perimenopause symptoms can affect sleep, mood, concentration, work and relationships, and when to seek personalised clinical support.
By Dr Rebecca Poet • October 6, 2026
Discover why strength training matters in menopause, with beginner exercises for muscle, bone, heart health and balance, plus practical HRT advice.
By Dr Ayana Gibbs • September 21, 2026
Discover why PCOS has been renamed PMOS, what the change means for diagnosis and metabolic health, and how emerging research may connect the condition with ADHD.
By Dr Susie Rockwell • September 18, 2026
Which menopause supplements actually work? An evidence-based guide to St John’s Wort, black cohosh, phytoestrogens, CBT, magnesium, omega-3 and more.
By Dr Rebecca Poet • September 16, 2026
Menopause is more than hot flushes. Learn how hormonal changes affect your heart, bones, bladder and brain — and how the right support can help you age well.
By Dr Kemi Adeyemi • September 6, 2026
Learn the key signs of gynaecological cancers, when to seek help, and how HPV vaccination, screening and new tests may support earlier diagnosis.